Insider Selling: Zimmer Biomet Holdings Inc (ZBH) VP Sells 20,826 Shares of Stock

Zimmer Biomet Holdings Inc (NYSE:ZBH) VP Chad F. Phipps sold 20,826 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Zimmer Biomet Holdings Inc (ZBH) traded up $0.42 on Wednesday, reaching $116.35. 220,800 shares of the company traded hands, compared to its average volume of 1,507,042. The company has a market capitalization of $23,592.16, a price-to-earnings ratio of 12.84, a PEG ratio of 2.05 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. Zimmer Biomet Holdings Inc has a 52-week low of $108.03 and a 52-week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting the consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same quarter last year, the firm earned $2.14 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. research analysts expect that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is 10.65%.

Large investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC grew its stake in shares of Zimmer Biomet by 18.6% in the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after acquiring an additional 1,057 shares during the last quarter. Ingalls & Snyder LLC boosted its stake in Zimmer Biomet by 2.6% during the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after buying an additional 507 shares in the last quarter. Jana Partners LLC boosted its stake in Zimmer Biomet by 16.6% during the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Zimmer Biomet by 10.0% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after buying an additional 1,494 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Zimmer Biomet during the third quarter worth $370,000. 86.36% of the stock is currently owned by institutional investors.

A number of research firms have recently issued reports on ZBH. Cantor Fitzgerald reissued a “buy” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Tuesday, January 30th. BMO Capital Markets reissued a “buy” rating and issued a $144.00 price target on shares of Zimmer Biomet in a research report on Tuesday, January 30th. Morgan Stanley increased their price target on shares of Zimmer Biomet from $140.00 to $150.00 in a research report on Monday, January 29th. SunTrust Banks increased their price target on shares of Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a research report on Monday, January 29th. Finally, Needham & Company LLC increased their price target on shares of Zimmer Biomet from $144.00 to $155.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $141.67.

WARNING: “Insider Selling: Zimmer Biomet Holdings Inc (ZBH) VP Sells 20,826 Shares of Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/insider-selling-zimmer-biomet-holdings-inc-zbh-vp-sells-20826-shares-of-stock.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply